{"disease":{"id":"myeloma-multiple","name":"myeloma multiple"},"drugs":{"marketed":[{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05283993","title":"A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT01345019","title":"Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1718,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06205823","title":"Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM","phase":"","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"Seoul St. Mary's Hospital","has_results":false},{"nct_id":"NCT05361694","title":"Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT01564537","title":"A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07283224","title":"Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT00644228","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":525,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06679101","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03158688","title":"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":466,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00114101","title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":460,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00098475","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06149910","title":"Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"All4Cure","has_results":false},{"nct_id":"NCT03089411","title":"Collection of Additional Data Followed the Study IFM 2013-04","phase":"","overall_status":"UNKNOWN","enrollment_count":340,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04004338","title":"Carfilzomib in Combination for the Treatment of RR MM","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Black Sea Hematology Association","has_results":false},{"nct_id":"NCT06171685","title":"MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Multiple Myeloma Research Consortium","has_results":false},{"nct_id":"NCT05495620","title":"Long-term KRd in Relapsed and/or Refractory Multiple Myeloma","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Dong-A University Hospital","has_results":false},{"nct_id":"NCT06559033","title":"Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT07319897","title":"A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03952091","title":"TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT05742217","title":"A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04364724","title":"CTFEA Myeloma Study","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT04952766","title":"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Centre Hospitalier Régional d'Orléans","has_results":false},{"nct_id":"NCT06971380","title":"Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Polina Stepensky","has_results":false},{"nct_id":"NCT07051850","title":"Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies","phase":"","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Sung-Soo Park","has_results":false},{"nct_id":"NCT04236063","title":"Rehabilitation Needs of the Malaysian Haematological Cancer Survivors","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"University of Malaya","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT07463807","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":162,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07247097","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03607643","title":"A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Leaf Vertical Inc.","has_results":false},{"nct_id":"NCT06119685","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT06838065","title":"Rehabilitation Management for Patients with Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT05651932","title":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"K36 Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07446777","title":"FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT03860038","title":"TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT05430945","title":"A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07096778","title":"Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"CellCentric Ltd.","has_results":false},{"nct_id":"NCT04184050","title":"Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT06245629","title":"Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05091372","title":"Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06911710","title":"The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT06232044","title":"Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05789303","title":"Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":83,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT04287855","title":"Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT04776330","title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06948084","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04271644","title":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05243212","title":"Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Sheba Medical Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}